Inactive Instrument

Square Pharmaceuticals Ltd Share Price Dhaka S.E.

Equities

Pharmaceuticals

End-of-day quote Dhaka S.E.
- BDT - Intraday chart for Square Pharmaceuticals Ltd

Financials

Sales 2024 * 71.02B 605M 47.61B Sales 2025 * 79.68B 678M 53.42B Capitalization 184B 1.57B 123B
Net income 2024 * 21.32B 181M 14.29B Net income 2025 * 24.37B 207M 16.34B EV / Sales 2024 * 2.59 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 2.31 x
P/E ratio 2024 *
8.84 x
P/E ratio 2025 *
7.56 x
Employees -
Yield 2024 *
4.93%
Yield 2025 *
5.41%
Free-Float 64.82%
More Fundamentals * Assessed data
Square Pharmaceuticals PLC. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Square Pharmaceuticals PLC. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Square Pharmaceuticals PLC. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Square Pharmaceuticals PLC. Recommends Cash Dividend for the Year Ended June 30, 2023 CI
Square Pharmaceuticals PLC Announces Contract Manufacturing Agreement with M/S Aristopharma Ltd CI
Square Pharmaceuticals Limited has Changed its Name to Square Pharmaceuticals PLC CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021 CI
Square Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2021 CI
Square Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended on June 30, 2021 CI
Square Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended March 31, 2021 CI
Square Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended December 31, 2020 CI
More news
Managers TitleAgeSince
Chief Executive Officer - 31/12/79
Director of Finance/CFO - -
Compliance Officer - -
Members of the board TitleAgeSince
Chief Executive Officer - 31/12/79
Chairman - 31/12/90
Director/Board Member - 31/12/90
More insiders
Square Pharmaceuticals PLC. is a Bangladesh-based pharmaceuticals company. The main activities of the Company are to manufacture and market generic pharmaceutical products, basic chemical products, and animal health products. It is also engaged in the marketing of crop care products. It operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all live species. Its Pharma products include Ace, Ace Plus, Ace Power, Aclitol Cozycap, Adryl, Acetram, Afun, Akicin, Alacot DS Eye Drops, Alacot Eye Drops, Alacot Max Eye Drops, Alarid Eye Drops, Alarid, Alice Lotion, among others. Its Herbal and Hutraceutical products include AmCivit, Antiscar, Arubin, Betaburn, Bioprem, Bolardi, Femony, Fitvit, Flemo Max, Flemo, Flemo Plus, Freezy, Lecor, Livolite, Maximilk, Monera, Redclov, Reli Balm, Revatol, among others. Its Agrovet and crop care products include Ace-Vet Bolus, Agrizeb 80 WP, Aqua Rock, Almex-Vet Bolus and Andopan Powder.
More about the company